Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown. Despite improved outcomes with 12 months of durvalumab, which has become the standard of care, new strategies to improve surv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Borys Hrinczenko, Jarushka Naidoo, Jason Chesney, Salma K Jabbour, Naomi Fujioka, Greg Durm, Apar Kishor Ganti, Hirva Mamdani, Mary Jo Fidler, Nasser H Hanna, Shadia Jalal, Ticiana A Leal, Sandra Althouse, Susan Perkins, Lawrence Feldman
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2025-07-01
Edice:	Journal for ImmunoTherapy of Cancer
On-line přístup:	https://jitc.bmj.com/content/13/7/e010316.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!